Considerations in glaucoma therapy: Fixed combinations versus their component medications

Clinical Ophthalmology

Volumn 4, Issue 1, 2010, Pages 1-9

  Higginbotham, Eve J ^a  

^a MOREHOUSE SCHOOL OF MEDICINE   (United States)

Author keywords

Adherence; Brimonidine; Fixed combination; Glaucoma; Intraocular pressure

Indexed keywords

BIMATOPROST; BIMATOPROST PLUS TIMOLOL; BRIMONIDINE; BRIMONIDINE PLUS TIMOLOL; DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; LATANOPROST; LATANOPROST PLUS TIMOLOL; PILOCARPINE; TIMOLOL; TIMOLOL PLUS TRAVOPROST; TRAVOPROST;

ALLERGIC CONJUNCTIVITIS; BLURRED VISION; CLINICAL TRIAL; COMPARATIVE STUDY; CONJUNCTIVAL HYPEREMIA; CONJUNCTIVITIS; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENING DOSAGE; EYE ALLERGY; EYE BURNING; EYE DISCOMFORT; EYE IRRITATION; EYE PAIN; GLAUCOMA; HEADACHE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MONOTHERAPY; MORNING DOSAGE; NIGHT VISION; PATIENT CARE; PATIENT COMPLIANCE; PUNCTATE KERATITIS; REVIEW; SIDE EFFECT; TASTE DISORDER; TREATMENT RESPONSE;

EID: 77953397193     PISSN: 11775467     EISSN: 11775483     Source Type: Book Series    
DOI: None     Document Type: Review

References (40)

1. Olthoff CM, Schouten JS, van de Borne BW, Webers CA. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. Ophthalmology. 2005;112(6):953-961.
2. Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology. 2005;112(5): 863-868.
3. Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Rate and determinants of 10-year persistence with antihypertensive drugs. J Hypertens. 2005;23(11):2101-2107.
4. Dezii CM. A retrospective study of persistence with single-pill combina tion therapy vs concurrent two-pill therapy in patients with hypertension. Manag Care. 2000;9(9 Suppl):2-6.
5. Taylor AA, Shoheiber O. Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCl versus comparable component-based therapy. Congest Heart Fail. 2003;9(6):324-332
6. Strahlman E, Tipping R, Vogel R. A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. International Dorzolamide Study Group. Arch Ophthalmol. 1995;113(8):1009-1016.
7. Boyle JE, Ghosh K, Gieser DK, Adamsons IA. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzolamide-Timolol Study Group. Ophthalmology. 1998;105(10):1945-1951
8. Clineschmidt CM, Williams RD, Snyder E, Adamsons IA. A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide. Dorzolamide-Timolol Combination Study Group. Ophthalmology. 1998;105(10):1952-1959.
9. Higginbotham EJ, Feldman R, Stiles M, Dubiner H Fixed Combi nation Investigative Group. Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trial. Arch Ophthalmol. 2002;120(7):915-922.
10. Pfeiffer N European Latanoprost Fixed Combination Study Group. A comparison of the fixed combination of latanoprost and timolol with its individual components. Graefes Arch Clin Exp Ophthalmol. 2002;240(11):893-899.
11. Sherwood MB, Craven ER, Chou C, et al. Twice-daily 0.2% brimonidine 0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch Ophthalmol. 2006;124(9):1230-1238.
12. Brandt JD, Cantor LB, Katz LJ, Batoosingh AL, Chou C, Bossowska I Ganfort Investigators Group II. Bimatoprost/timolol fixed combination: a 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension. J Glaucoma. 2008;17(3):211-216.
13. Barnebey HS, Orengo-Nania S, Flowers BE, et al. The safety and effi cacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution. Am J Ophthalmol. 2005;140(1):1-7.
14. Hutzelmann J, Owens S, Shedden A, Adamsons I, Vargas E; Comparison of the safety and efficacy of the fixed combination of dorzolamide/timolol and the concomitant administration of dorzolamide and timolol: a clinical equivalence study. International Clinical Equiva lence Study Group. Br J Ophthalmol. 1998;82(11):1249-1253
15. Strohmaier K, Snyder E, DuBiner H, Adamsons I. The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Dorzolamide-Timolol Study Group. Ophthalmology. 1998;105(10):1936-1944.
16. Choudri S, Wand M, Shields MB. A comparison of dorzolamide timolol combination versus the concomitant drugs. Am J Ophthalmol. 2000;130(6):832-833.
17. Martone J, Mead A. Combination treatment may improve efficacy. Rev Ophthalmol. 2001;8(September):82-84.
18. Bacharach J, Delgado MF, Iwach AG. Comparison of the efficacy of the fixed-combination timolol/dorzolamide versus concomitant administration of timolol and dorzolamide. J Ocul Pharmacol Ther. 2003;19(2):93-96.
19. Francis BA, Du LT, Berke S, Ehrenhaus M, Minckler DS; Cosopt Study Group. Comparing the fixed combination dorzolamide-timolol (Cosopt) to concomitant administration of 2% dorzolamide (Trusopt) and 0.5% timolol a randomized controlled trial and a replacement study. J Clin Pharm Ther. 2004;29(4):375-380.
20. Magacho L, Reis R, Shetty RK, Santos LC, Avila MP. Efficacy of latanoprost or fixed-combination latanoprost-timolol in patients switched from a combination of timolol and a nonprostaglandin medication. Ophthalmology. 2006;113(3):442-445.
21. Diestelhorst M, Larsson LI European Latanoprost Fixed Combination Study Group. A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension. Br J Ophthalmol. 2004;88(2):199-203.
22. Diestelhorst M, Larsson LI European-Canadian Latanoprost Fixed Combination Study Group. A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components. Ophthalmology. 2006;113(1):70-76.
23. Motolko MA. Comparison of allergy rates in glaucoma patients receiving brimonidine 0.2% monotherapy versus fixed-combination brimonidine 0.2%-timolol 0.5% therapy. Curr Med Res Opin. 2008;24(9):2663-2667.
24. Goni FJ; Brimonidine/Timolol Fixed Combination Study Group. 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension. Eur J Ophthalmol. 2005;15(5):581-590
25. Hommer A Ganfort Investigators Group I. A double-masked, random ized, parallel comparison of a fixed combination of bimatoprost 0.03%/ timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertension. Eur J Ophthalmol. 2007;17(1):53-62
26. Schuman JS, Katz GJ, Lewis RA, et al. Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2005;140(2):242-250.
27. Hughes BA, Bacharach J, Craven ER, et al. A three-month, multi center, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension. J Glaucoma. 2005;14(5):392-399.
28. Ahmed I. CEED II: an in-depth look at the latest findings. Clin Surg J Ophthalmol. 2007;25(1):1-5.
29. Chan K, Testa M, McCluskey P. Ocular comfort of combination glaucoma therapies: brimonidine 0.2%/timolol 0.5% compared with dorzolamide 2%/timolol 0.5%. J Ocul Pharmacol Ther. 2007;23(4):372-376.
30. Shafi T, Koay P. Randomised prospective masked study comparing patient comfort following the instillation of topical proxymetacaine and amethocaine. Br J Ophthalmol. 1998;82(11):1285-1287
31. Silver LH. Ocular comfort of brinzolamide 1.0% ophthalmic suspension compared with dorzolamide 2.0% ophthalmic solution: results from two multicenter comfort studies. Brinzolamide Comfort Study Group. Surv Ophthalmol. 2000;44 Suppl 2:S141-S145.
32. Arcieri ES, Arcieri RS, Pereira AC, Andreo EG, Finotti IG, Sá Filho WF. Comparing the fixed combination brimonidine-timolol versus fixed combination dorzolamide-timolol in patients with elevated intraocular pressure. Curr Med Res Opin. 2007;23(4):683-689.
33. Nixon DR, Yan DB, Chartrand JP, Piemontesi RL, Simonyi S, Hollander DA. Three-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed-combination therapy. Curr Med Res Opin. 2009;25(7):1645-1653.
34. Lesk MR, Koulis T, Sampalis F, Sampalis JS, Bastien NR. Effectiveness and safety of dorzolamide-timolol alone or combined with latanoprost in open-angle glaucoma or ocular hypertension. Ann Pharmacother. 2008;42(4):498-504.
35. McKee HD, Gupta MS, Ahad MA, Saldaña M, Innes JR. First-choice treatment preferences for primary open-angle glaucoma in the United Kingdom. Eye. 2005;19(8):923-924.
36. Patel SC, Spaeth GL. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg. 1995;26(3):233-236.
37. Sleath B, Robin AL, Covert D, Byrd JE, Tudor G, Svarstad B. Patient reported behavior and problems in using glaucoma medications. Ophthalmology. 2006;113(3):431-436.
38. Gellad WF, Haas JS, Safran DG. Race/ethnicity and nonadherence to prescription medications among seniors: results of a national study. J Gen Intern Med. 2007;22(11):1572-1578.
39. Fiscella RG, Green A, Patuszynski DH, Wilensky J. Medical therapy cost considerations for glaucoma. Am J Ophthalmol. 2003;136(1):18-25
40. Rylander NR, Vold SD. Cost analysis of glaucoma medications. Am J Ophthalmol. 2008;145(1):106-113.